Following the development of secondary resistance to IM (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), non-selective kinase inhibitors targeting VEGFR, PDGFR, and c-KIT are recommended for second- and third-line GIST treatment, respectively. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.